- Home
- ACIU vs PLBY Comparison
ACIU vs PLBY Comparison
Compare ACIU & PLBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACIU | PLBY |
|---|---|---|
| Founded | 2003 | 1953 |
| Country | Switzerland | United States |
| Employees | N/A | 588 |
| Industry | Biotechnology: Pharmaceutical Preparations | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 211.0M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACIU | PLBY |
|---|---|---|
| Price | $2.85 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $10.00 | $3.00 |
| AVG Volume (30 Days) | 252.0K | ★ 809.7K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $120,928,000.00 |
| Revenue This Year | $706.75 | $9.17 |
| Revenue Next Year | $321.13 | $7.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 4.13 |
| 52 Week Low | $1.55 | $0.93 |
| 52 Week High | $4.00 | $2.75 |
Technical Indicators
Market Signals| Indicator | ACIU | PLBY |
|---|---|---|
| Relative Strength Index (RSI) | 45.07 | 57.94 |
| Support Level | $2.56 | $1.63 |
| Resistance Level | $2.99 | $1.99 |
| Average True Range (ATR) | 0.21 | 0.11 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 13.19 | 68.67 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About PLBY PLBY Group Inc.
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.